Diurnal Group PLC Exercise of Options, Issue of Equity and TVR (5328O)
08 Octubre 2021 - 06:24AM
UK Regulatory
TIDMDNL
RNS Number : 5328O
Diurnal Group PLC
08 October 2021
8 October 2021
Diurnal Group plc
("Diurnal" or the "Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical
company targeting patient needs in chronic endocrine (hormonal)
diseases, announces that it has issued 150,111 new ordinary shares
of 5 pence each ("New Ordinary Shares") as a result of an exercise
of options under the Company's Long Term Incentive Plan
("LTIP").
Application has been made for admission of the 150,111 New
Ordinary Shares to trading on AIM, which is anticipated to occur at
8:00am on or around 12 October 2021 ("Admission"). The New Ordinary
Shares will rank pari passu with the existing shares of common
stock of the Company. Following Admission, the Company's issued
ordinary share capital will consist of 169,053,801 ordinary shares.
The Company does not hold any shares in treasury. Therefore, the
total number of ordinary shares with voting rights in Diurnal
following Admission will be 169,053,801.
The above figure of 169,053,801 may be used by shareholders as
the denominator for the calculations by which they will determine
if they are required to notify their interest in, or a change to
their interest in the Company under the FCA's Disclosure Guidance
and Transparency Rules.
For further information, please visit www.diurnal.co.uk or
contact:
+44 (0)20 3727
Diurnal Group plc 1000
Martin Whitaker, Chief Executive Officer
Richard Bungay, Chief Financial Officer
Panmure Gordon (UK) Limited (Nominated Adviser +44 (0)20 7886
and Sole Broker) 2500
Corporate Finance: Freddy Crossley, Emma Earl
Corporate Broking: Rupert Dearden
+44 (0)20 3727
FTI Consulting (Media and Investor Relations) 1000
Simon Conway
Victoria Foster Mitchell
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-headquartered, European
specialty pharma company developing high quality products for the
global market for the life-long treatment of chronic endocrine
conditions, including congenital adrenal hyperplasia, adrenal
insufficiency and hypogonadism. Its expertise and innovative
research activities focus on circadian-based endocrinology to yield
novel product candidates in the rare and chronic endocrine disease
arena.
For further information about Diurnal, please visit
www.diurnal.co.uk
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRUWUARAAURRAA
(END) Dow Jones Newswires
October 08, 2021 07:24 ET (11:24 GMT)
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Diurnal (LSE:DNL)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024